• Rezolute flagged four ENDO 2026 presentations, led by a Phase 3 sunRIZE oral update on ersodetug in congenital hyperinsulinism.
• The sunRIZE talk will present previously reported top-line results, keeping the focus on clinical benefit rather than new disclosures.
• Additional posters will outline disease burden in congenital hyperinsulinism, aiming to support the commercial case for treatment adoption.
• A separate poster will present a compassionate-use case series in malignant insulin-secreting tumors, signaling potential expansion beyond congenital disease.
• All presentations are scheduled for June 13-16, 2026, in Chicago, with the Phase 3 oral session set for June 13.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.